BioCentury | Jan 23, 2021
Management Tracks

Yale’s Fuchs joins Genentech, Roche; plus Lineage’s Roberts jumps on Longboard as CFO and Avidity, Xalud, AVM, Novavax

Charles “Charlie” Fuchs is joining Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit as SVP and global head of product development for oncology and hematology. Fuchs, who will start March 1 and be based in South San Francisco, is...
BioCentury | Jan 23, 2021
Product Development

Why COVID master protocols haven’t been productive in the U.S., and how to fix it

If the U.S. hopes to generate substantial, meaningful data on therapies for COVID-19 and future pandemics, it will need to overhaul the clinical trial ecosystem to prioritize master protocols.  At...
BioCentury | Jan 22, 2021
Product Development

Jan. 22 Quick Takes: CDC updates advice on COVID vaccine dosing; plus more vaccines for COVAX and RCC approval for Opdivo-Cabometyx and more

CDC said the second dose of COVID-19 vaccines from Moderna Inc. (NASDAQ:MRNA) and partners BioNTech SE (NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE) can be administered up to six weeks after the first dose. The prior recommendation had been three...
BioCentury | Jan 20, 2021
Product Development

RA readout drives Aclaris’ first big gain since shifting focus to innovative immunology pipeline

An efficacy readout in a small Phase IIa trial of Aclaris’ oral therapy for rheumatoid arthritis has more than tripled the company’s market cap, representing its first major value-creating event since it restructured in 2H19...
BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

Chi-Med, Inmagene partner on immunological indicationsHutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) granted Inmagene Biopharmaceuticals Co. Ltd. exclusive options to four immunological diseases programs for up to $95 million in development milestones, $135 million in commercial...
BioCentury | Jan 9, 2021
Finance

Gracell looks to NASDAQ IPO to place it among CAR T leaders

Gracell has followed fellow CAR T companies Legend, Allogene and bluebird onto NASDAQ with an oversubscribed IPO that the Suzhou company hopes will help put it on the map as a global player in the space....
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

Pacific Biosciences of California Inc. (NASDAQ:PACB) filled two newly created posts via the hiring of a pair of Illumina Inc. (NASDAQ:ILMN) veterans: Mark Van Oene as COO and Peter Fromen as chief commercial officer. Van Oene...
BioCentury | Jan 8, 2021
Finance

Crossovers back Affinivax in $236M round as more pipeline vaccines move toward clinic

A $236 million crossover round could set up Affinivax for a public listing as the biotech looks to take more vaccines into the clinic beyond its partnered pneumococcal program. Rock Springs Capital and Foresite Capital...
BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

With crossover investors lining up to participate, biotechs Immuneering, Terns and Ikena each raised rounds that could augur upcoming public offerings. The deals come as a host of biotechs will likely...
BioCentury | Jan 5, 2021
Product Development

Crucible of COVID, ahoy 2021 & cancer deal trends: a BioCentury podcast

The New Year kicks off with the new — a new U.S. president readying to enter the White House with a new take on drug pricing, and investors eyeing new modalities — and too much of the...
Items per page:
1 - 10 of 2496